Stock Events

Stock Events

Bonus BioGroup 

$0.040000
2
+$0.01+33.33%Thursday 16:34

Statistics

Day High
0.02
Day Low
0.02
52W High
0.15
52W Low
0.02
Volume
10,000
Avg. Volume
222
Mkt Cap
46.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Sep 30Expected
Q3 2017
Q3 2018
Q2 2019
Q3 2019
Q2 2020
Q3 2020
Q2 2021
-0.01
-0
-0
0
Expected EPS
N/A
Actual EPS
-0.0062

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.47MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap1.97B
Mesoblast Limited specializes in regenerative medicine using mesenchymal lineage cells, competing in the same therapeutic areas as Bonus BioGroup.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics works on stem cell therapies for neurodegenerative diseases, overlapping with some of Bonus BioGroup's therapeutic applications.
Mimedx Group
MDXG
Mkt Cap566.19M
MiMedx Group, Inc. provides regenerative biomaterials and bioimplants, directly competing with Bonus BioGroup's tissue regeneration technologies.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation produces autologous cell therapies for treatment of severe diseases and conditions, similar to Bonus BioGroup's approach in regenerative medicine.
Fate Therapeutics
FATE
Mkt Cap249.23M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, competing in the broader field of advanced biotechnologies like Bonus BioGroup.
Adaptive Biotechnologies
ADPT
Mkt Cap4.25B
Adaptive Biotechnologies Corp. works on the immune-driven medicine space, indirectly competing with Bonus BioGroup's focus on innovative biotechnological treatments.

About

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Show More
CEO
Shai Meretzki
Employees
42
Country
Israel
ISIN
IL0004850116

Listings

TA
IL
BONS.TA
OTC Link
US
BBIXF

0 Comments

Share your thoughts

FAQs

What is Bonus BioGroup stock price today?▼
The current price of BBIXF is $0.04 USD — it has increased by +33.33% in the past 24 hours. Watch Bonus BioGroup stock price performance more closely on the chart.
What is Bonus BioGroup stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Bonus BioGroup stocks are traded under the ticker BBIXF.
Is Bonus BioGroup stock price growing?▼
BBIXF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Bonus BioGroup has showed a -50% decrease.
What is Bonus BioGroup market cap?▼
Today Bonus BioGroup has the market capitalization of 46.72M
What were Bonus BioGroup earnings last quarter?▼
BBIXF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bonus BioGroup revenue for the last year?▼
Bonus BioGroup revenue for the last year amounts to 0 USD.
What is Bonus BioGroup net income for the last year?▼
BBIXF net income for the last year is -7.47M USD.
How many employees does Bonus BioGroup have?▼
As of November 2, 2026, the company has 42 employees.
In which sector is Bonus BioGroup located?▼
Bonus BioGroup operates in the Health & Wellness sector.
When did Bonus BioGroup complete a stock split?▼
The last stock split for Bonus BioGroup was on June 3, 2012 with a ratio of 1:10.
Where is Bonus BioGroup headquartered?▼
Bonus BioGroup is headquartered in Haifa, Israel.